Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C1261473
Disease: Sarcoma
Sarcoma 		0.010 AlteredExpression group BEFREE Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression of MicroRNA 200s and GRHL2. 27402864 2016
CUI: C1858723
Disease: Poikiloderma with Neutropenia
Poikiloderma with Neutropenia 		0.010 GeneticVariation disease BEFREE Our case series shows that biallelic variants in USB1, LIG4 and GRHL2, the genes mutated in poikiloderma with neutropenia, LIG4/Dubowitz syndrome and the recently recognized ectodermal dysplasia/short stature syndrome, respectively, cause features that overlap with dyskeratosis congenita. 27612988 2016
CUI: C4275242
Disease: Sudden sensorineural hearing loss
Sudden sensorineural hearing loss 		0.010 GeneticVariation disease BEFREE GRHL2 genetic polymorphisms, rs611419 and rs10955255, have a protective role against SSHL and reduce the risk of SSHL. 26847018 2016
CUI: C4551686
Disease: Malignant neoplasm of soft tissue
Malignant neoplasm of soft tissue 		0.010 AlteredExpression group BEFREE Mesenchymal-Epithelial Transition in Sarcomas Is Controlled by the Combinatorial Expression of MicroRNA 200s and GRHL2. 27402864 2016
CUI: C0007847
Disease: Malignant tumor of cervix
Malignant tumor of cervix 		0.010 Biomarker disease BEFREE However, further studies are needed to delineate the role of GRHL2 in cervical cancer and during malignant progression. 25550776 2014
CUI: C0034069
Disease: Pulmonary Fibrosis
Pulmonary Fibrosis 		0.010 Biomarker disease BEFREE Our findings reveal important pathophysiological differences between human IPF and specific mouse models of fibrosis and support a crucial role of GRHL2 in epithelial activation in lung fibrosis and perhaps also in epithelial plasticity. 24375798 2014
CUI: C0302592
Disease: Cervix carcinoma
Cervix carcinoma 		0.010 Biomarker disease BEFREE However, further studies are needed to delineate the role of GRHL2 in cervical cancer and during malignant progression. 25550776 2014
CUI: C0740457
Disease: Malignant neoplasm of kidney
Malignant neoplasm of kidney 		0.010 Biomarker disease BEFREE Using an integrative system biology approach, we identified 3 novel factors as potential biomarkers (AHR, GRHL2 and KIAA0101) involved in ccRCC pathogenesis and not linked to kidney cancer before. 25139457 2014
CUI: C1378703
Disease: Renal carcinoma
Renal carcinoma 		0.010 Biomarker disease BEFREE Using an integrative system biology approach, we identified 3 novel factors as potential biomarkers (AHR, GRHL2 and KIAA0101) involved in ccRCC pathogenesis and not linked to kidney cancer before. 25139457 2014
CUI: C1800706
Disease: Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis 		0.010 Biomarker disease BEFREE Our findings reveal important pathophysiological differences between human IPF and specific mouse models of fibrosis and support a crucial role of GRHL2 in epithelial activation in lung fibrosis and perhaps also in epithelial plasticity. 24375798 2014
CUI: C2931488
Disease: Zlotogora-Ogur syndrome
Zlotogora-Ogur syndrome 		0.010 GeneticVariation disease BEFREE Mutations in GRHL2 result in an autosomal-recessive ectodermal Dysplasia syndrome. 25152456 2014
CUI: C4048328
Disease: cervical cancer
cervical cancer 		0.010 Biomarker disease BEFREE However, further studies are needed to delineate the role of GRHL2 in cervical cancer and during malignant progression. 25550776 2014
CUI: C0346957
Disease: Disseminated Malignant Neoplasm
Disseminated Malignant Neoplasm 		0.010 AlteredExpression phenotype BEFREE Grhl2 is down-regulated in disseminated cancer cells that have undergone EMT, and over-expression of Grhl2 is sufficient to induce epithelial gene expression. 23284647 2012
CUI: C0242379
Disease: Malignant neoplasm of lung
Malignant neoplasm of lung 		0.010 AlteredExpression disease BEFREE By using a series of silencing and overexpression studies, we show that EDD1 and GRHL2 suppress death-receptor expression, and that EDD1 expression is elevated in breast, pancreas, and lung cancer cell lines resistant to death receptor-mediated apoptosis. 21949371 2011
CUI: C0684249
Disease: Carcinoma of lung
Carcinoma of lung 		0.010 AlteredExpression disease BEFREE By using a series of silencing and overexpression studies, we show that EDD1 and GRHL2 suppress death-receptor expression, and that EDD1 expression is elevated in breast, pancreas, and lung cancer cell lines resistant to death receptor-mediated apoptosis. 21949371 2011
CUI: C1306460
Disease: Primary malignant neoplasm of lung
Primary malignant neoplasm of lung 		0.010 AlteredExpression disease BEFREE By using a series of silencing and overexpression studies, we show that EDD1 and GRHL2 suppress death-receptor expression, and that EDD1 expression is elevated in breast, pancreas, and lung cancer cell lines resistant to death receptor-mediated apoptosis. 21949371 2011
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.010 Biomarker disease BEFREE A gain of GRHL2 might be a predictive marker for HCC recurrence. 18752864 2008
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma 		0.010 Biomarker disease LHGDN A gain of GRHL2 might be a predictive marker for HCC recurrence. 18752864 2008
CUI: C0235974
Disease: Pancreatic carcinoma
Pancreatic carcinoma 		0.020 Biomarker disease BEFREE GRHL2 may serve an important role in the tumourigenesis of PC and serve as a potential therapeutic target for the prevention of PC progression. 30675204 2019
CUI: C4722085
Disease: Malignant neoplasm of colon and/or rectum
Malignant neoplasm of colon and/or rectum 		0.020 Biomarker disease BEFREE GRHL2 inhibits colorectal cancer progression and metastasis via oppressing epithelial-mesenchymal transition. 31063022 2019
CUI: C4722085
Disease: Malignant neoplasm of colon and/or rectum
Malignant neoplasm of colon and/or rectum 		0.020 Biomarker disease BEFREE Knockdown of GRHL2 inhibited proliferation and induced apoptosis of colorectal cancer by suppressing the PI3K/Akt pathway. 30917932 2019
CUI: C0007137
Disease: Squamous cell carcinoma
Squamous cell carcinoma 		0.020 Biomarker disease BEFREE Both GRHL2 and FoxM1B were strongly induced in the epidermis of HPV-16 E6 transgenic mice and HPV<sup>+</sup> oral squamous cell carcinomas. 29443638 2018
CUI: C0027794
Disease: Neural Tube Defects
Neural Tube Defects 		0.020 GeneticVariation group BEFREE Grainyhead-like genes represent candidates for involvement in NTDs based on the presence of SB and exencephaly in mice carrying loss-of-function alleles of Grhl2 or Grhl3. 30189017 2018
CUI: C0040411
Disease: Tongue Neoplasms
Tongue Neoplasms 		0.020 Biomarker group BEFREE When exposed to 4-nitroquinoline 1-oxide (4-NQO), a strong chemical carcinogen, Grhl2 wild-type (WT) mice developed rampant oral tongue tumors, while Grhl2 KO mice completely abolished tumor development. 29735981 2018
CUI: C0040411
Disease: Tongue Neoplasms
Tongue Neoplasms 		0.020 AlteredExpression group BEFREE However, 4-NQO exposure failed to induce tongue tumors or induction of FoxM1B expression in Grhl2 KO mice. 29443638 2018